Modified irinotecan and infusional 5-fluorouracil (mFOLFIRI) in patients with refractory advanced pancreas cancer (APC): a single-institution experience.

about

Modified irinotecan and infusional 5-fluorouracil (mFOLFIRI) in patients with refractory advanced pancreas cancer (APC): a single-institution experience.

Item

http://www.wikidata.org/entity/Q37157946

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 19 March 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Modified irinotecan and infusi ...... single-institution experience.

@en

Modified irinotecan and infusional 5-fluorouracil

@nl

type

Item

label

Modified irinotecan and infusi ...... single-institution experience.

@en

Modified irinotecan and infusional 5-fluorouracil

@nl

prefLabel

Modified irinotecan and infusi ...... single-institution experience.

@en

Modified irinotecan and infusional 5-fluorouracil

@nl

P1476

Modified irinotecan and infusi ...... single-institution experience.

@en

P2093

C Wu

http://www.w3.org/2001/XMLSchema#string

D A Goldstein

http://www.w3.org/2001/XMLSchema#string

D H Ahn

http://www.w3.org/2001/XMLSchema#string

J A Stephens

http://www.w3.org/2001/XMLSchema#string

J Reardon

http://www.w3.org/2001/XMLSchema#string

K K Ciombor

http://www.w3.org/2001/XMLSchema#string

M Bupathi

http://www.w3.org/2001/XMLSchema#string

T Bekaii-Saab

http://www.w3.org/2001/XMLSchema#string

P2860

State of the art biological therapies in pancreatic cancer

Cancer statistics, 2015

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

Pilot study of irinotecan/oxalipltin (IROX) combination chemotherapy for patients with gemcitabine- and 5-fluorouracil- refractory pancreatic cancer.

Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group.

First- and second-line bevacizumab in addition to chemotherapy for metastatic colorectal cancer: a United States-based cost-effectiveness analysis.

FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-salts.

P2888

s12032-016-0753-9

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12032-016-0753-9

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-03-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26995224

http://www.w3.org/2001/XMLSchema#string

P921

Aizkuņģa dziedzeris

P932

4976592

http://www.w3.org/2001/XMLSchema#string